Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs

Core Insights - Agenus Inc. has triggered a $20 million contingent payment under its strategic collaboration with Zydus Lifesciences Ltd. [1] - The payment is linked to contracted work orders for critical chemistry, manufacturing, and controls (CMC) and production activities related to botensilimab (BOT) and balstilimab (BAL) [1] Company Summary - Agenus Inc. is recognized as a leader in immuno-oncology innovation [1] - The collaboration with Zydus Lifesciences is focused on advancing the development of botensilimab and balstilimab [1]